<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic Colorectal Cancer</z:e> (mCRC), in which <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> are KRAS mutated, have no response to anti-EGFR therapy </plain></SENT>
<SENT sid="1" pm="."><plain>However, less than half of mCRC patients with KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> respond to anti-EGFR therapy </plain></SENT>
<SENT sid="2" pm="."><plain>Other downstream effectors of the EGFR pathway are being analyzed to fine-tune KRAS predictive value </plain></SENT>
<SENT sid="3" pm="."><plain>However, as the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> is the tissue of analysis that determines the use of anti-EGFR therapy in advanced disease, a high concordance in the status of these effectors between <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> and related <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> is required </plain></SENT>
<SENT sid="4" pm="."><plain>We analyzed the concordances of downstream EGFR effectors in tumoral pairs of primaries and related <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> in a series of KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> patients </plain></SENT>
<SENT sid="5" pm="."><plain>One hundred seventeen tumoral pairs from patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> were tested for KRAS mutational status </plain></SENT>
<SENT sid="6" pm="."><plain>The level of concordance in the presence of KRAS mutations was 91% between the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> and related <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The 70 pairs with KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> were further analyzed for BRAF and PIK3CA mutational status and for EGFR, PTEN and pAKT expression, and the number of concordant pairs was 70 (100%), 66 (94%), 43 (61%), 46 (66%) and 36 (54%), respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Our findings suggest that the mutational status of KRAS, BRAF and PIK3CA in the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> is an adequate surrogate marker of the status in the <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>On the other hand, the immunohistochemical analysis of EGFR, PTEN and pAKT showed a much higher degree of discordance between primaries and related <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
</text></document>